転移し外科的に切除できないHER2陽性乳がんの参加者を対象としたパトリツマブ デルクステカンと他の抗がん剤の併用研究(MK-1022-009)
HERTHENA-Breast-01: HER2 陽性切除不能な局所進行乳がんまたは転移性乳がんの参加者におけるパトリツマブ デルクステカンの安全性と抗腫瘍活性を評価するための第 1b/2 相、多施設共同、非盲検、用量設定研究
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
調査の概要
状態
詳細な説明
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Toll Free Number
- 電話番号:1-888-577-8839
- メール:Trialsites@msd.com
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
コンタクト:
- Study Coordinator
- 電話番号:720-848-1030
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana-Farber Cancer Institute ( Site 0050)
-
コンタクト:
- Study Coordinator
- 電話番号:877-338-7425
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08901
- 募集
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
コンタクト:
- Study Coordinator
- 電話番号:732-235-2465
-
-
South Carolina
-
Greenville、South Carolina、アメリカ、29605
- 募集
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
コンタクト:
- Study Coordinator
- 電話番号:864-455-3600
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Inova Schar Cancer Institute ( Site 0051)
-
コンタクト:
- Study Coordinator
- 電話番号:571-472-4724
-
-
-
-
Camden
-
London、Camden、イギリス、NW1 2PG
- 募集
- University College London Hospital ( Site 0041)
-
コンタクト:
- Study Coordinator
- 電話番号:+442034472930
-
-
Glasgow City
-
Glasgow、Glasgow City、イギリス、G12 0YN
- 募集
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
コンタクト:
- Study Coordinator
- 電話番号:+441413017000
-
-
London, City of
-
London、London, City of、イギリス、EC1A 7BE
- 募集
- St Bartholomew s Hospital ( Site 0040)
-
コンタクト:
- Study Coordinator
- 電話番号:+442073777000
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Health Care Campus ( Site 0011)
-
コンタクト:
- Study Coordinator
- 電話番号:04-7776234
-
Petah Tikva、イスラエル、4941492
- 募集
- Rabin Medical Center ( Site 0012)
-
コンタクト:
- Study Coordinator
- 電話番号:+972-505533121
-
Ramat Gan、イスラエル、5265601
- 募集
- Sheba Medical Center ( Site 0010)
-
コンタクト:
- Study Coordinator
- 電話番号:03-5304498
-
-
-
-
Ontario
-
Kingston、Ontario、カナダ、K7L 2V7
- 募集
- Kingston General Hospital ( Site 0061)
-
コンタクト:
- Study Coordinator
- 電話番号:6135336541
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- Princess Margaret Cancer Centre ( Site 0001)
-
コンタクト:
- Study Coordinator
- 電話番号:416-946-4501
-
-
Quebec
-
Montreal、Quebec、カナダ、H3T 1E2
- 募集
- Jewish General Hospital ( Site 0003)
-
コンタクト:
- Study Coordinator
- 電話番号:514-340-8222
-
Montreal、Quebec、カナダ、H2X 3E4
- 募集
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
コンタクト:
- Study Coordinator
- 電話番号:(514)890-8000 x20737
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、467-8602
- 募集
- Nagoya City University Hospital ( Site 0020)
-
コンタクト:
- Study Coordinator
- 電話番号:+81-52-851-5511
-
-
-
-
-
Seoul、韓国、03080
- 募集
- Seoul National University Hospital ( Site 0030)
-
コンタクト:
- Study Coordinator
- 電話番号:82-2-2072-0850
-
Seoul、韓国、05505
- 募集
- Asan Medical Center ( Site 0031)
-
コンタクト:
- Study Coordinator
- 電話番号:+82-2-1688-7575
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
他の名前:
Trastuzumab administered via IV infusion
他の名前:
Trastuzumab biosimilar administered via IV infusion
他の名前:
|
|
実験的:Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
他の名前:
Trastuzumab administered via IV infusion
他の名前:
Trastuzumab biosimilar administered via IV infusion
他の名前:
Pertuzumab administered via IV infusion |
|
実験的:Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
他の名前:
Trastuzumab administered via IV infusion
他の名前:
Trastuzumab biosimilar administered via IV infusion
他の名前:
Tucatinib administered as oral tablets |
|
実験的:Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
他の名前:
Trastuzumab administered via IV infusion
他の名前:
Trastuzumab biosimilar administered via IV infusion
他の名前:
Pertuzumab administered via IV infusion |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
時間枠:Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
時間枠:Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
時間枠:Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
時間枠:Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
時間枠:At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
時間枠:Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
時間枠:Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
時間枠:Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
時間枠:Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
協力者と研究者
スポンサー
協力者
捜査官
- スタディディレクター:Medical Director、Merck Sharp & Dohme LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 1022-009
- MK-1022-009 (その他の識別子:MSD)
- jRCT2041250022 (レジストリ識別子:Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (レジストリ識別子:EU CT)
- U1111-1346-4321 (レジストリ識別子:UTN)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。